{"doi":"10.3390/cancers15030976","title":"Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients","abstract":"Post-transplant lymphoproliferative disorders (PTLD) are heterogenous lymphoproliferative disorders that develop as a consequence of immunosuppression in transplant recipients. We sought to determine if subtypes of PTLD correlated with different outcomes. We performed a retrospective review of PTLD occurring in pediatric heart transplant recipients. A total of 558 children and infants underwent cardiac transplantation at our institution between 1985 and 2019 and were followed until March 2021. Forty-nine of 558 patients developed PTLD (8.8%). As compared to older children (>one year of age), infant recipients (<three months of age) were less likely to develop PTLD. Monomorphic PTLDs (M-PTLD, 61%) was the most common subtype at initial diagnosis, followed by non-destructive (21%), polymorphic (14%), and classic Hodgkin lymphoma (cHL, 4%). Patients who underwent transplantation at a young age (<three months) had significantly lower rates of M-PTLD or cHL and a longer time from transplant to PTLD diagnosis as compared to children older than one year at transplant (p = 0.04). Although not reaching statistical significance, patients with a shorter time to PTLD diagnosis showed a trend toward higher rates of M-PTLD or cHL. As expected, the overall survival (OS) of patients with M-PTLD or cHL was significantly lower than patients with non-destructive or polymorphic PTLD.","journal":"Cancers","year":2023,"id":18167,"datarank":0.7683349201265312,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"self_citation_contribution":0.44166584687496613,"citation_network_contribution":0.326669073251565,"self_endowment_contribution":0.44166584687496613,"citer_contribution":0.326669073251565,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":18,"citers_with_citation_signal":13,"citers_with_endowment":13,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":127287,"name":"Billy C. Wang","orcid":"0000-0002-0733-0892","position":1,"is_corresponding":false},{"id":127288,"name":"Craig W. Zuppan","orcid":null,"position":2,"is_corresponding":false},{"id":127289,"name":"Peter Chau","orcid":null,"position":3,"is_corresponding":false},{"id":127290,"name":"James Fitts","orcid":null,"position":4,"is_corresponding":false},{"id":127291,"name":"Richard Chinnock","orcid":"0000-0002-9814-1762","position":5,"is_corresponding":false},{"id":6308,"name":"Jun Wang","orcid":"0000-0003-2509-9599","position":6,"is_corresponding":false},{"id":127087,"name":"Yan Liu","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36765933","pmcid":"PMC9913467","openalex_id":"https://openalex.org/W4319082491","authors":[],"funders":[],"total_grants":0,"fwci":3.9079,"citation_percentile":0.93932367,"influential_citations":0,"citation_trend":[{"year":2023,"count":6},{"year":2024,"count":4},{"year":2025,"count":6},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2072-6694/15/3/976/pdf?version=1675411943","host_type":"journal"},{"url":"https://www.mdpi.com/2072-6694/15/3/976/pdf?version=1675411943","host_type":"GOLD"},{"url":"https://www.mdpi.com/2072-6694/15/3/976/pdf?version=1675411943","host_type":"publisher"},{"url":"https://www.mdpi.com/2072-6694/15/3/976/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/cancers15030976","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36765933","host_type":"repository"},{"url":"https://escholarship.org/uc/item/4qq064zx","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9913467","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/cancers15030976","host_type":"repository"},{"url":"https://escholarship.org/content/qt4qq064zx/qt4qq064zx.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9913467/pdf/cancers-15-00976.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9913467","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9913467?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Viral-associated cancers and disorders","Polyomavirus and related diseases","Transplantation: Methods and Outcomes","Medicine"],"mesh_terms":[],"keywords":["Lymphoproliferative disorders","Medicine","Post-transplant lymphoproliferative disorder","Retrospective cohort study","Internal medicine","Pediatrics","Lymphoma","Rituximab","Survival","CMV","EBV","Lymphoproliferative Disorder","Heart Transplant","Post-transplant"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-03T18:58:04.984112Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}